ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Consumer Discretionary / AMN / insiders
ASTH (57) NSP (31) ICFI (74) EFOR (71) ⌘ Pro Terminal β†’

AMN Healthcare Services Inc (AMN) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$45.77 -2.84% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $45.45

AMN Healthcare Services Inc (AMN) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ β€’ SELL / AVOID Cap $1.82B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AMN Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is AMN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, AMN Healthcare Services Inc (NYSE: AMN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $45.77 (-2.84% 1D, market cap $1.82B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1009 tracked Consumer Discretionary issuers, AMN ranks #418 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does AMN compare to ASTH and NSP in the Consumer Discretionary sector?
β–Ό

Within the Consumer Discretionary sector (Professional Services), AMN carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 28.3%, and ROIC of -7.2%. By comparison, ASTH (Astrana Health Inc.) holds a D+ grade (57/100 RQD, P/E 75.7x, ROIC 4.6%, cap $1.81B) and NSP (Insperity Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -8.9%, cap $1.85B). Among the 5-stock peer group, EFOR leads on earnings multiple (13.4x) while ICFI leads on capital efficiency (8.1% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AMN?
β–Ό

Per AMN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001142750), AMN Healthcare Services Inc generated $2.73B in revenue (-8.5% YoY), -$95.7M in net income, and $233.8M in free cash flow against $2.09B in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $45.45 (-0.70%)🧬 Disciplined Float (-0.40% YoY Shares)βš™οΈ Cash Engine: 9/20 (D) β€’ 8.6% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY β€’ 51.8% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D+
025507510056
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D+ Β· Rk D+
Cash (9)Whales (16)SEC (10)Macro (12)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-0.9% Base Target
$54 Bull$45 Base$35 Bear
πŸ“¬ FREE AMN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for AMN)Realized 20D OHLCV Swing Band: Β±9.5%
Deterministic 5-Pillar Attribution (56/100 Composite)
πŸ” WHY AMN SCORES 56/100 (D+) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+16/20 pts (29% of score)

20D Institutional Volume Accumulation (Β±9.5% realized swing band)

β–² #2 Bullish Driver: Macro Regime Fit+12/20 pts (21% of score)

FRED Regime Γ— Technicals: 89% of 52W Range β€’ RSI-14 at 75.2 (OVERBOUGHT (>70))

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
48
Grade D$36.54+13.9% Next Q
Q2 (-2Q)
51
Grade C-$41.62+12.5% Next Q
Q3 (-1Q)
53
Grade C-$46.81-2.2% Next Q
Current
56
Grade D+$45.77-0.4% Hist 90D Ξ±
Trajectory: D (48) β†’ D+ (56)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the AMN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 56/100 (D+) score, AMN faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($37.72) or 200D SMA ($28.74) invalidates the momentum regime and cuts Target Base ($45.36) toward Bear Floor ($35.38).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMNβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œAMN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 56%NO 44%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

AMN Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (AMN)

No recent open-market Form 4 cluster sales or emergency dumps flagged on AMN. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AMN)

  • βœ“Walkthrough of AMN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
AMN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +120.90%β–² ASCENDING CHANNEL
2026-11-03O $46.94H $47.11L $45.77C $45.77VOL 599.0K
RES: $50.39SUP: $36.08SMA50: $37.72SMA200: $28.74
$51.78$42.83$33.88$24.93$15.98RES $50.39SUP $36.08$45.772026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ AMN Butterfly Map β†’ + Track AMN β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -8.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AMN today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for AMN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AMN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMN)

Consumer Discretionary Rank #418 of 1009 βš”οΈ ASTH vs AMN Full Matrix β†’

1. Head-to-Head Consumer Discretionary Peer Comparison (AMN vs. ASTH, NSP, ICFI, EFOR)

Industry: Professional Services (48 Tracked Issuers)

Across 1009 tracked Consumer Discretionary securities in the Roarable RQD universe, AMN Healthcare Services Inc (AMN) ranks #418 by composite RQD confidence (56/100, grade D+) and #424 by equity capitalization ($1.82B). Within this direct 5-issuer industry benchmark cohort, EFOR leads on earnings valuation at 13.4x trailing P/E, while ICFI leads on capital efficiency and profitability with 8.1% ROIC and 37.2% gross margin. ICFI currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with AMN at 56/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AMN ACTIVE
AMN Healthcare Services Inc
D+ 56/100 β€” 28.3% -7.2% -2.84% $1.82B Benchmark Subject
ASTH
Astrana Health Inc.
D+ 57/100 75.7x β€” 4.6% +0.96% $1.81B /asth-vs-amn β†’
NSP
Insperity Inc.
E 31/100 β€” 13.2% -8.9% +9.24% $1.85B /nsp-vs-amn β†’
ICFI
ICF International Inc.
B 74/100 18.7x 37.2% 8.1% +3.18% $1.71B /icfi-vs-amn β†’
EFOR
Everforth Inc.
B- 71/100 13.4x 28.9% 6.5% -1.78% $1.57B /efor-vs-amn β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001142750 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), AMN Healthcare Services Inc (AMN) reported GAAP revenue of $2.73B (-8.5% vs. FY2024 revenue of $2.98B , and -27.9% cumulative change since FY2023) , GAAP net income of -$95.7M, operating cash flow of $269.5M, and free cash flow of $233.8M (-2.4% YoY). On the balance sheet, AMN closed FY2025 with $2.09B in total assets against $0 in total debt (Altman Z-Score: 2.76, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.73B -$95.7M $269.5M $233.8M $2.09B β€”
FY2024 (FY) 2024-12-31 $2.98B -$147.0M $320.4M $239.5M $2.42B β€”
FY2023 (FY) 2023-12-31 $3.79B $210.7M $372.2M $372.2M β€” β€”

3. AMN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, AMN Healthcare Services Inc (NYSE: AMN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $45.77 (-2.84% 1D, market cap $1.82B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1009 tracked Consumer Discretionary issuers, AMN ranks #418 in composite RQD confidence.

How does AMN compare to ASTH and NSP in the Consumer Discretionary sector?

Within the Consumer Discretionary sector (Professional Services), AMN carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 28.3%, and ROIC of -7.2%. By comparison, ASTH (Astrana Health Inc.) holds a D+ grade (57/100 RQD, P/E 75.7x, ROIC 4.6%, cap $1.81B) and NSP (Insperity Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -8.9%, cap $1.85B). Among the 5-stock peer group, EFOR leads on earnings multiple (13.4x) while ICFI leads on capital efficiency (8.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AMN?

Per AMN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001142750), AMN Healthcare Services Inc generated $2.73B in revenue (-8.5% YoY), -$95.7M in net income, and $233.8M in free cash flow against $2.09B in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AMN trading relative to its 50-day, 200-day, and 52-week technical levels?

AMN last traded at $45.77 (-2.84% on volume of 977,345 shares), positioning the stock +21.34% above its 50-day simple moving average ($37.72) and +59.26% above its 200-day simple moving average ($28.74). Across its 52-week range of $14.97 to $49.62, AMN sits at the 88.9% percentile with a 14-day RSI of 75.2 (OVERBOUGHT (>70)) and an implied next-earnings move of Β±9.5% ($41.42 to $50.12).

Direct Sub-Reports: AMN RQD Cockpit AMN 12M Forecast AMN Earnings & Move AMN Dividends & DRIP AMN Insiders & 13F AMN Whale Options AMN Profit Sankey AMN News & Why
ROARABLE RATING BRIEF β€’ RQD 56/100 (D+) βœ“ SEC XBRL & RQD VERIFIED

AMN β€” AMN Healthcare Services Inc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

AMN Healthcare Services Inc (AMN) earns a live Roarable RQD composite score of 56/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $45.77 (-2.84% 1D, market capitalization $1.82B).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -7.2%, gross margin of 28.3%, operating margin of -2.0%, and free cash flow yield of 12.86%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.76, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

AMN Healthcare Services Inc (AMN) is a NYSE-listed operating company in the Professional Services industry (Consumer Discretionary sector) with an equity market capitalization of $1.82B. The business operates with a gross margin of 28.3%, an operating margin of -2%, and a return on invested capital (ROIC) of -7.2% (free cash flow yield of 12.86%). Within the Professional Services peer group, investor evaluation centers on operating leverage, unit margin durability, and capital allocation efficiency across market cycles.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), AMN Healthcare Services Inc (AMN) reported $2.73B in annual revenue (up from $2.98B in FY2024, -8.5% YoY) and -$95.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.79B revenue, $210.7M net income) through FY2025, AMN scaled operating cash flow to $269.5M and free cash flow to $233.8M, backed by $2.09B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D+ β€’ RQD 56/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of 12.86% and institutional whale pillar of 16/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $14.97 – $49.62 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -2.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply_chain value is NONE, butterfly_links is empty, and proprietary_signals is empty. The source data therefore identifies no upstream or downstream dependencies, no sector correlations beyond the Consumer Discretionary / Professional Services classification, and no 2nd-order bottlenecks. Any such analysis would require source data not provided.

  • Key Question #1: Can AMN sustain or expand its -2.0% operating margin and -7.2% ROIC against Professional Services peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.73B and free cash flow of $233.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is AMN's equity valuation to Consumer Discretionary capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

AMN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for AMN Healthcare Services Inc (AMN) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to AMN Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AMN Bull vs. Bear Conversation Board β€” What's Your Call at $45.77?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AMN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AMN:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER β€’ Verified $100K Arena Trader πŸ‚ BULLISH 🎯 Target: $54.18 (+15.0%)
πŸ“Œ Pinned Debate

Institutional accumulation, a 12.86% FCF yield, and a stock near its 52-week high signal market conviction despite reported losses.

Institutional accumulation, a 12.86% FCF yield, and a stock near its 52-week high signal market conviction despite reported losses.. When you look under the hood at AMN, Fundamental Cash Engine is 9/20 with 28.3% gross margins and -7.2% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (16/20) has been quietly accumulating below $49.62. My 12M target is $54.18.

SectorRotator πŸ‚ BULL

@AlphaFlow_Cap Agree on the RQD 56/100 quality, though with 1.0 beta I'm scaling in with half-size at $47.11 and keeping dry powder in case we test $43.81.

CR CreditSpread_Watch RQD DEBATE OPENER β€’ Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $37.69 (-20.0%)
Spot @ $47.11

Negative ROIC of -7.2%, net losses in FY 2024 and FY 2025, and a revenue decline from $3.79B to $2.73B undercut the fundamentals be

Fading this rally in AMN at $47.11. Negative ROIC of -7.2%, net losses in FY 2024 and FY 2025, and a revenue decline from $3.79B to $2.73B undercut the fundamentals behind the price run.. With a beta of 1.0 and the stock sitting at $47.11 (52-wk range $14.97–$49.62), the easy multiple expansion is already priced in.

LIVE TAPE